Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

Sorafenib in Advanced Hepatocellular Carcinoma

2008 • 11,718 citations

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

1996 • 6,878 citations

Sorafenib in Advanced Hepatocellular Carcinoma

2008 • 5,675 citations

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 • 5,572 citations

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 • 4,669 citations

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 • 2,500 citations

Angiogenesis: an organizing principle for drug discovery?

2007 • 2,179 citations

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

2006 • 1,431 citations

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

2005 • 1,140 citations

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 • 1,030 citations

Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

2003 • 598 citations

The hierarchical relationship between activities of daily living and instrumental activities of daily living

1987 • 557 citations

Cutaneous side-effects of kinase inhibitors and blocking antibodies

2005 • 539 citations

Common Terminology Criteria for Adverse Events v3.0 (CTCAE)

2008 • 450 citations

Quality of Life in Patients with Psoriasis: A Systematic Literature Review

2004 • 420 citations

12. Index of ADL

1976 • 339 citations

Antineoplastic Therapy???Induced Palmar Plantar Erythrodysesthesia (???Hand-Foot???) Syndrome

2000 • 279 citations

Expression of c-kit and kit ligand proteins in normal human tissues.

1994 • 260 citations

Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

2004 • 246 citations

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

2007 • 235 citations

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

2008 • 229 citations

Development and validation of a quality of life instrument for cutaneous diseases

1997 • 199 citations

Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis

2008 • 189 citations

Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy

1995 • 173 citations

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

2007 • 168 citations

Human keratinocytes are a major source of cutaneous platelet-derived growth factor.

1993 • 149 citations

Uncovering Pandora’s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib

2007 • 146 citations

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

2007 • 142 citations

Convergent and Discriminant Validity of a Generic and a Disease-Specific Instrument to Measure Quality of Life in Patients with Skin Disease

1997 • 129 citations

Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer

2007 • 115 citations

Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib

2008 • 110 citations

Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis.

1996 • 98 citations

Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis

2009 • 91 citations

Epithelial-Stromal Interactions in Basal Cell Cancer: The PDGF System

1994 • 90 citations

Antiangiogenic Agents: an Update on Small Molecule VEGFR Inhibitors

2007 • 82 citations

Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans

2003 • 78 citations

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

2006 • 73 citations

The measurement of Instrumental ADL: Content validity and construct validity

1993 • 63 citations

Spiny keratoderma of the palms and soles

1992 • 60 citations

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

2005 • 60 citations

The pathogenesis of psoriasis and the mechanism of action of tazarotene

1998 • 58 citations

Localized Palmar–Plantar Epidermal Hyperplasia: A Previously Undefined Dermatologic Toxicity to Sorafenib

2007 • 43 citations

Yellow Skin Discoloration Associated with Sorafenib Use for Treatment of Metastatic Renal Cell Carcinoma

2007 • 41 citations

Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib

2007 • 35 citations

Managing Side Effects of Angiogenesis Inhibitors in Renal Cell Carcinoma

2007 • 33 citations

Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results

2007 • 29 citations

Sorafenib: A Promising New Targeted Therapy for Renal Cell Carcinoma

2007 • 24 citations

Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: Impact on quality of life (QoL)

2008 • 22 citations

Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial

2006 • 21 citations

Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand?foot syndrome?

2007 • 17 citations